Equities

Sol Gel Technologies Ltd

Sol Gel Technologies Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.75
  • Today's Change0.011 / 1.46%
  • Shares traded48.87k
  • 1 Year change-78.51%
  • Beta1.5213
Data delayed at least 15 minutes, as of May 17 2024 20:56 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.

  • Revenue in USD (TTM)1.55m
  • Net income in USD-27.24m
  • Incorporated1997
  • Employees36.00
  • Location
    Sol Gel Technologies LtdGolda Meir 7NESS-ZIONA 7403650IsraelISR
  • Phone+972 89313433
  • Fax+972 89313434
  • Websitehttp://www.sol-gel.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Evaxion Biotech A/S - ADR73.00k-22.13m19.40m49.00------265.75-81.29-81.290.2665-1.250.0042--0.0911,489.80-126.74-100.11-183.85-131.65-----30,308.22-131,560.30---30.921.77------4.51--65.53--
Indaptus Therapeutics Inc0.00-14.98m19.72m7.00--2.11-----1.78-1.780.001.100.00----0.00-87.86-66.55-97.46-81.23------------0.00-------7.68------
Goldenwell Biotech Inc2.34k-116.90k19.80m----233.71--8,461.54-0.0012-0.00120.000020.00090.00980.0071-----49.07---52.16--47.01---4,995.73--37.75--0.00---95.10--88.13------
Cocrystal Pharma Inc0.00-16.75m19.84m12.00--0.8784-----1.65-1.650.002.220.00----0.00-52.03-50.94-56.92-52.77-------1,501.78----0.00------53.69--33.34--
Nymox Pharmaceutical Corp0.00-4.87m20.23m3.00---------0.0536-0.05360.00-0.02040.00-------255.75-264.40---464.48-------13,001.67---42.44--------47.55------
Vincerx Pharma Inc0.00-40.16m20.40m42.00--1.32-----1.89-1.890.000.52420.00----0.00-103.63---128.01--------------0.00------36.24------
AIM ImmunoTech Inc202.00k-28.96m20.51m26.00--2.07--101.52-0.595-0.5950.00420.20840.0068--0.14137,769.23-96.75-45.64-116.18-48.3579.21-231.75-14,337.62-11,695.01----0.00--43.26-11.26-48.94--35.73--
Lumos Pharma Inc1.53m-37.13m20.62m33.00--1.18--13.52-4.59-4.590.18862.150.0332--8.0146,212.12-80.89-29.78-90.15-32.32-----2,434.69-2,937.61----0.00--34.67-30.31-9.57------
Polypid Ltd0.00-24.25m20.70m59.00--2.90-----12.35-12.350.001.490.00----0.00-84.94-76.92-120.03-89.61-----------28.720.5498------39.67---42.34--
Sol Gel Technologies Ltd1.55m-27.24m20.89m36.00--0.5407--13.44-1.02-1.020.05741.390.0338--0.377443,166.67-59.27-31.60-64.80-35.49-----1,752.77-135.76----0.00---59.9864.50-82.52---33.78--
Neurosense Therapeutics Ltd0.00-11.28m20.97m16.00---------0.7625-0.76250.00-0.12190.00----0.00-207.24---395.72----------------------8.59------
MEI Pharma Inc66.75m26.16m20.99m46.000.80250.41130.79170.31443.933.9310.027.660.6498--29.151,451,174.0025.46-25.3130.38-28.59----39.18-122.05----0.00--19.9597.5641.53------
Cumberland Pharmaceuticals, Inc.38.83m-8.42m21.43m91.00--0.7778--0.5519-0.596-0.5962.721.940.45420.88123.08426,654.70-9.83-7.03-14.07-9.5283.5479.95-21.65-17.641.21-37.100.3717---5.856.15-12.73---36.17--
Forte Biosciences Inc0.00-32.14m21.90m11.00--0.7625-----1.03-1.030.000.78820.00----0.00-93.54-72.06-104.30-82.27-------491,850.00----0.00-------126.79---46.29--
Bioxytran Inc0.00-4.30m21.92m2.00---------0.0297-0.02970.00-0.00170.00-------2,431.80-1,420.53---------------7.69---------73.71------
Bullfrog AI Holdings, Inc.65.00k-5.95m22.37m4.00--3.29--344.22-0.8903-0.89030.00970.86670.0094----16,250.00-85.49---103.85--92.00---9,129.42-----278.200.0694--550.00---91.11------
Data as of May 17 2024. Currency figures normalised to Sol Gel Technologies Ltd's reporting currency: US Dollar USD

Institutional shareholders

27.45%Per cent of shares held by top holders
HolderShares% Held
Phoenix Investments House Ltd.as of 31 Mar 20242.57m9.24%
Armistice Capital LLCas of 31 Mar 20242.08m7.46%
Migdal Insurance Co. Ltd. (Investment Portfolio)as of 31 Mar 20241.23m4.41%
Harel Mutual Funds Ltd.as of 31 Mar 2024920.33k3.30%
Kingdon Capital Management LLCas of 31 Mar 2024481.75k1.73%
Yelin Lapidot Mutual Fund Management Ltd.as of 31 Mar 2024229.18k0.82%
Raymond James Financial Services Advisors, Inc.as of 31 Mar 202449.13k0.18%
Morgan Stanley & Co. LLCas of 31 Mar 202433.71k0.12%
Raymond James & Associates, Inc. (Invt Mgmt)as of 31 Mar 202430.98k0.11%
Millennium Management LLCas of 31 Mar 202420.40k0.07%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.